The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Oleynikova N.A.

Lomonosov Moscow State University

Sycheva I.N.

Lomonosov Moscow State University

Mikhailov I.A.

Lomonosov Moscow State University;
Center of Expertise and Quality Control of Healthcare

Zhestkov I.A.

Lomonosov Moscow State University

Varenzov M.G.

Lomonosov Moscow State University

Malkov P.G.

Lomonosov Moscow State University;
Russian Medical Academy of Continuous Professional Education

Patterns of CAF expression in tumors of the genitourinary system

Authors:

Oleynikova N.A., Sycheva I.N., Mikhailov I.A., Zhestkov I.A., Varenzov M.G., Malkov P.G.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2024;86(6): 28‑35

DOI: 10.17116/patol20248606128

Read: 1996 times

Download PDF (RU)
Contact the author
Table of contents

PATTERNS OF CAF EXPRESSION IN TUMORS OF THE GENITOURINARY SYSTEM
PATTERNS OF CAF EXPRESSION IN TUMORS OF THE GENITOURINARY SYSTEM

To cite this article:

Oleynikova NA, Sycheva IN, Mikhailov IA, Zhestkov IA, Varenzov MG, Malkov PG. Patterns of CAF expression in tumors of the genitourinary system. Russian Journal of Archive of Pathology. 2024;86(6):28‑35. (In Russ.)
https://doi.org/10.17116/patol20248606128

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The impact of combined immu­notherapy on the cellular composition of the tumor microenvironment in patients with gastric carcinoma. Russian Journal of Archive of Pathology. 2025;(4):24-30
Characteristics of the immune microenvironment of endo­metrial cancer depe­nding on the MMR status of the tumor. Russian Journal of Archive of Pathology. 2025;(5):11-19
Using the PathVision.ai model of medi­cal deci­sion support in morphological diagnostics of prostate cancer in biopsy mate­rial. Russian Journal of Archive of Pathology. 2025;(6):34-41
Primary lymphoma of the central nervous system. Russian Journal of Archive of Pathology. 2025;(6):56-60
Remote resu­lts of treatment of patients with prostate cancer who unde­rwent radiation therapy in a combined version. P.A. Herzen Journal of Onco­logy. 2025;(3):14-19
Epidemiology and prevention of prostate cancer. Russian Journal of Preventive Medi­cine. 2025;(7):111-118
Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):83-92
Global coagulation tests in pharmacological prophylaxis of venous thro­mboembolism in patients with prostate cancer after radi­cal prostatectomy. P.A. Herzen Journal of Onco­logy. 2025;(5):41-46
Abstract:

Cancer-associated fibroblasts (CAF), as the most important component of the tumor microenvironment, have been the subject of targeted study in recent years. There is increasing evidence of CAF heterogeneity and their different roles in tumor progression. However, there is no single marker identifying CAF, and there is also no understanding of the similarity of CAF markers in various tumors of the genitourinary system.

OBJECTIVE

To evaluate the response of CAF markers — FAP and PDGFRα+β in bladder cancer and prostate cancer.

MATERIAL AND METHODS

An immunohistochemical study with antibodies to FAP and PDGFRα+β was conducted on material from 34 patients with prostate cancer and 44 patients with bladder cancer in order to identify statistical relationships with stage, morphological characteristics and survival, as well as to understand the applicability of the same markers for cancer of different localizations.

RESULTS

An increased FAP reaction was shown in prostate cancer with metastases (p=0.0239), a significantly higher number of recurrences in the group with a high PDGFRa+β (3+) reaction (p=0.0018); the presence of FAP reaction only in invasive bladder cancers (p=0.0094) and bladder cancers with high grade dysplasia (p=0.0000234), the absence of a relationship between the level of PDGFRa+β and clinical and morphological characteristics in bladder cancer.

CONCLUSION

Our results confirm the heterogeneity of CAF in both bladder and prostate tumors and indicate that FAP is one of CAF subpopulation marker.

Considering that FAP is expressed in a population of CAFs that lead to resistance to treatment with immune checkpoint inhibitors in melanoma, the FAP marker may also be diagnostically significant for tumors of the genitourinary system, especially given the fact that bladder tumors are treated with the BCG vaccine.

Keywords:

bladder cancer
prostate cancer
cancer-associated fibroblasts
tumor microenvironment
tumor stroma

Authors:

Oleynikova N.A.

Lomonosov Moscow State University

Sycheva I.N.

Lomonosov Moscow State University

Mikhailov I.A.

Lomonosov Moscow State University;
Center of Expertise and Quality Control of Healthcare

Zhestkov I.A.

Lomonosov Moscow State University

Varenzov M.G.

Lomonosov Moscow State University

Malkov P.G.

Lomonosov Moscow State University;
Russian Medical Academy of Continuous Professional Education

Received:

29.05.2024

Accepted:

26.06.2024

Close metadata

References:

  1. Rimal R, Desai P, Daware R, Hosseinnejad A, Prakash J, Lammers T, Singh S. Cancer-associated fibroblasts: origin, function, imaging, and therapeutic targeting. Adv Drug Deliv Rev. 2022;189:114504. https://doi.org/10.1016/j.addr.2022.114504
  2. Glabman RA, Choyke PL, Sato N. Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers (Basel). 2022;14(16):3906. https://doi.org/10.3390/cancers14163906
  3. Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y. Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5(6):628-639.  https://doi.org/10.1016/j.euo.2022.10.003
  4. Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, Stattin P, Van Poppel H, La Vecchia C. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877-892.  https://doi.org/10.1016/j.euo.2021.09.006
  5. Calvete J, Larrinaga G, Errarte P, Martin AM, Dotor A, Esquinas C, Nunes-Xavier CE, Pulido R, Lopez JI, Angulo JC. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Hum Pathol. 2019; 91:61-68.  https://doi.org/10.1016/j.humpath.2019.07.002
  6. Caramelo B, Zagorac S, Corral S, Marques M, Real FX. Cancer-associated fibroblasts in bladder cancer: origin, biology, and therapeutic opportunities. Eur Urol Oncol. 2023;6(4):366-375.  https://doi.org/10.1016/j.euo.2023.02.011
  7. Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579-596.  https://doi.org/10.1084/jem.20162024
  8. Pan J, Ma Z, Liu B, Qian H, Shao X, Liu J, Wang Q, Xue W. Identification of cancer-associated fibroblasts subtypes in prostate cancer. Front Immunol. 2023;14:1133160. https://doi.org/10.3389/fimmu.2023.1133160
  9. Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, Sirven P, Magagna I, Fuhrmann L, Bernard C, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463-479.e10.  https://doi.org/10.1016/j.ccell.2018.01.011
  10. Liu F, Qi L, Liu B, Liu J, Zhang H, Che D, Cao J, Shen J, Geng J, Bi Y, et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS One. 2015; 10(3):e0116683. https://doi.org/10.1371/journal.pone.0116683
  11. Chen S, Zhu G, Yang Y, Wang F, Xiao YT, Zhang N, Bian X, Zhu Y, Yu Y, Liu F, et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol. 2021;23(1):87-98.  https://doi.org/10.1038/s41556-020-00613-6
  12. Bartoschek M, Oskolkov N, Bocci M, Lovrot J, Larsson C, Sommarin M, Madsen CD, Lindgren D, Pekar G, Karlsson G, et al. Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 2018;9(1):5150. https://doi.org/10.1038/s41467-018-07582-3
  13. Strell C, Paulsson J, Jin SB, Tobin NP, Mezheyeuski A, Roswall P, Mutgan C, Mitsios N, Johansson H, Wickberg SM, et al. Impact of epithelial-stromal interactions on peritumoral fibroblasts in ductal carcinoma in situ. J Natl Cancer Inst. 2019;111(9):983-995.  https://doi.org/10.1093/jnci/djy234
  14. Corvigno S, Frodin M, Wisman GBA, Nijman HW, Van der Zee AG, Jirstrom K, Nodin B, Hrynchyk I, Edler D, Ragnhammar P, et al. Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker. J Pathol Clin Res. 2017;3(3):214-224.  https://doi.org/10.1002/cjp2.74
  15. Paulsson J, Ryden L, Strell C, Frings O, Tobin NP, Fornander T, Bergh J, Landberg G, Stal O, Ostman A. High expression of stromal PDGFRbeta is associated with reduced benefit of tamoxifen in breast cancer. J Pathol Clin Res. 2016;3(1):38-43.  https://doi.org/10.1002/cjp2.56
  16. Mezheyeuski A, Segersten U, Leiss LW, Malmstrom PU, Hatina J, Ostman A, Strell C. Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome. Sci Rep. 2020;10(1):281.  https://doi.org/10.1038/s41598-019-55013-0
  17. Herrera M, Herrera A, Dominguez G, Silva J, Garcia V, Garcia JM, Gomez I, Soldevilla B, Munoz C, Provencio M, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013;104(4):437-444.  https://doi.org/10.1111/cas.12096
  18. Mhawech-Fauceglia P, Yan L, Sharifian M, Ren X, Liu S, Kim G, Gayther SA, Pejovic T, Lawrenson K. Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer. Cancer Microenviron. 2015;8(1):23-31.  https://doi.org/10.1007/s12307-014-0153-7
  19. Shi M, Yu DH, Chen Y, Zhao CY, Zhang J, Liu QH, Ni CR, Zhu MH. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol. 2012;18(8):840-846.  https://doi.org/10.3748/wjg.v18.i8.840
  20. Barrett R, Pure E. Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy. Curr Opin Immunol. 2020;64:80-87.  https://doi.org/10.1016/j.coi.2020.03.004
  21. Chen Y, Kim J, Yang S, Wang H, Wu CJ, Sugimoto H, LeBleu VS, Kalluri R. Type I collagen deletion in alphaSMA(+) myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell. 2021;39(4):548-565.e6.  https://doi.org/10.1016/j.ccell.2021.02.007
  22. Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, Esaki N, Ushida K, Mii S, Shiraki Y, et al. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res. 2019;79(20):5367-5381. https://doi.org/10.1158/0008-5472.CAN-19-0454
  23. Nicolas AM, Pesic M, Engel E, Ziegler PK, Diefenhardt M, Kennel KB, Buettner F, Conche C, Petrocelli V, Elwakeel E, et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell. 2022;40(2):168-184.e13.  https://doi.org/10.1016/j.ccell.2022.01.004
  24. McAndrews KM, Chen Y, Darpolor JK, Zheng X, Yang S, Carstens JL, Li B, Wang H, Miyake T, Correa de Sampaio P, et al. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer. Cancer Discov. 2022;12(6):1580-1597. https://doi.org/10.1158/2159-8290.CD-20-1484
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.